Organization
Oryzon Genomics
2 clinical trials
1 abstract
Clinical trial
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical TrialStatus: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
"A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)"Status: Completed, Estimated PCD: 2023-10-30
Abstract
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.Org: Massachusetts General Hospital, Harvard Medical School, Oryzon Genomics, Cornella De Llobregat, Barcelona Clinic Liver Cancer,